ULORIC targets gout
by taking uric acid lower.

ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia. ULORIC is not for everyone. Individual results may vary.

SIMPLE, ONCE-
DAILY DOSING

DEMONSTRATED EFFICACY:

KEY DIFFERENCES:
ULORIC VS ALLOPURINOL

ULORIC powerfully lowers serum uric acid to target levels of <6 mg/dL8.1 In the largest Phase 3 Study (6 Months):

45% of patients who received ULORIC 40 mg achieved serum uric acid level <6 mg/dL (N=757) compared to 42% of patients who received allopurinol 300 mg (N=755; p=0.233).

67% of patients who received ULORIC 80 mg achieved serum uric acid level <6 mg/dL (N=756) compared to 42% of patients who received allopurinol 300 mg (N=755; p<0.001).

Individual results may vary based on factors such as baseline serum uric acid levels. See data for patients with baseline serum uric acid ≥ 10 mg/dL.

Important Safety Information

ULORIC is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline.
An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC. If a gout flare occurs during treatment, ULORIC need not be discontinued. Prophylactic therapy (i.e. - NSAIDs or colchicine) upon initiation of treatment may be beneficial for up to six months.
Cardiovascular Events: In randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC [0.74 per 100 P-Y (95% CI 0.36-1.37)] than allopurinol [0.60 per 100 P-Y (95% CI 0.16-1.53)]. A causal relationship with ULORIC has not been established. Monitor for signs and symptoms of MI and stroke.
Liver Enzyme Elevations: In randomized controlled studies, transaminase elevations greater than 3 times the upper limit of normal (ULN) were observed (AST: 2%, 2%, and ALT: 3%, 2% in ULORIC and allopurinol-treated patients, respectively). No dose-effect relationship for these transaminase elevations was noted. Laboratory assessment of liver function is recommended at, for example, 2 and 4 months following initiation of ULORIC and periodically thereafter.
Adverse reactions occurring in at least 1% of ULORIC-treated patients, and, at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.

Please see complete Prescribing Information.

ULORIC^® is a registered trademark of Teijin Pharma Limited and used under license by Takeda Pharmaceuticals America, Inc.
All other trademark names are the property of their respective owners.

ULORIC targets gout by taking uric acid lower.

SIMPLE, ONCE-DAILY DOSING

DEMONSTRATED EFFICACY:

KEY DIFFERENCES:ULORIC VS ALLOPURINOL

Important Safety Information

ULORIC targets gout
by taking uric acid lower.

SIMPLE, ONCE-
DAILY DOSING

KEY DIFFERENCES:
ULORIC VS ALLOPURINOL